Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1978 1
1979 2
1980 2
1981 4
1985 3
1987 1
1991 2
1994 2
1995 5
1996 2
1999 2
2000 2
2004 2
2005 1
2007 1
2008 2
2009 3
2010 1
2011 2
2012 2
2013 4
2014 3
2015 2
2016 7
2017 9
2018 18
2019 10
2020 13
2021 13
2022 8
2023 7
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

126 results

Results by year

Filters applied: . Clear all
Page 1
Targeting HIF-2 Alpha in Renal Cell Carcinoma.
Ahmed R, Ornstein MC. Ahmed R, et al. Among authors: ornstein mc. Curr Treat Options Oncol. 2023 Sep;24(9):1183-1198. doi: 10.1007/s11864-023-01106-y. Epub 2023 Jul 5. Curr Treat Options Oncol. 2023. PMID: 37403008 Review.
Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial.
Larkin J, Oya M, Martignoni M, Thistlethwaite F, Nathan P, Ornstein MC, Powles T, Beckermann KE, Balar AV, McDermott D, Gupta S, Philips GK, Gordon MS, Uemura H, Tomita Y, Wang J, Michelon E, di Pietro A, Choueiri TK. Larkin J, et al. Among authors: ornstein mc. Oncologist. 2023 Apr 6;28(4):333-340. doi: 10.1093/oncolo/oyac243. Oncologist. 2023. PMID: 36576173 Free PMC article. Clinical Trial.
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B).
Atkins MB, Jegede OA, Haas NB, McDermott DF, Bilen MA, Stein M, Sosman JA, Alter R, Plimack ER, Ornstein MC, Hurwitz M, Peace DJ, Signoretti S, Denize T, Cimadamore A, Wu CJ, Braun D, Einstein D, Catalano PJ, Hammers H. Atkins MB, et al. Among authors: ornstein mc. J Immunother Cancer. 2023 Mar;11(3):e004780. doi: 10.1136/jitc-2022-004780. J Immunother Cancer. 2023. PMID: 36948504 Free PMC article. Clinical Trial.
The Immunotherapy Landscape in Renal Cell Carcinoma.
Brown LC, Desai K, Zhang T, Ornstein MC. Brown LC, et al. Among authors: ornstein mc. BioDrugs. 2020 Dec;34(6):733-748. doi: 10.1007/s40259-020-00449-4. BioDrugs. 2020. PMID: 33048299 Review.
Menstrual suppression in special circumstances.
Kirkham YA, Ornstein MP, Aggarwal A, McQuillan S; CANPAGO COMMITTEE. Kirkham YA, et al. Among authors: ornstein mp. J Obstet Gynaecol Can. 2014 Oct;36(10):915-924. doi: 10.1016/S1701-2163(15)30442-4. J Obstet Gynaecol Can. 2014. PMID: 25375306 Review.
Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
Brown LC, Zhu J, Desai K, Kinsey E, Kao C, Lee YH, Pabla S, Labriola MK, Tran J, Dragnev KH, Tafe LJ, Dayyani F, Gupta RT, McCall S, George DJ, Glenn ST, Nesline MK, George S, Zibelman M, Morrison C, Ornstein MC, Zhang T. Brown LC, et al. Among authors: ornstein mc. J Immunother Cancer. 2022 Oct;10(10):e005249. doi: 10.1136/jitc-2022-005249. J Immunother Cancer. 2022. PMID: 36252996 Free PMC article.
126 results